Surrozen to Present at Upcoming Healthcare Investor Conference
Globe Newswire•06/11/2026•16:40 ET
1
Key Highlights
- ➤Surrozen (SRZN) management to present at Guggenheim’s 3rd Annual Healthcare Innovation Conference
- ➤Fireside chat scheduled November 10, 2026, at 1:30 PM Pacific Time
- ➤Surrozen expects cash runway into 2029, including planned clinical development
- ➤DUET Phase 1b/2a study first patient dosing planned in fourth quarter of 2026
- ➤Initial DUET study data anticipated in the second half of 2027
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
Guggenheim’s 3(rd) Annual Healthcare Innovation Conference on Tuesday, November 10, 2026
Get started
Create a free account to read the full story.